ITB-MED AB
559017-9429ActiveDeveloping novel antibody therapy to eliminate post-transplant immunosuppression needs.
Oversigt
- 10–19
- Medarbejdere
- 50–100mio SEK
- Omsætning
- 2015
- Grundlagt
Beskrivelse
ITB-MED is a specialized biotechnology company focused on transforming organ transplantation outcomes. The organization is developing TCD601 (siplizumab), a proprietary antagonistic CD2-directed monoclonal antibody. This novel therapy aims to achieve transplantation tolerance, potentially freeing pa...
Tags
Nøgleord
Virksomhedsoplysninger
- Branche
- Annan naturvetenskaplig och teknisk forskning och utveckling
- Juridisk form
- Aktiebolag
- Momsnummer
- SE559017942901
Beslutningstagere
Ingen beslutningstagere fundet endnu
Lignende virksomheder
20 lignende virksomheder i FunnelfeedriCoat Medical AB
1–4 medarbejdereDeveloping drugs to improve organ transplantation outcomes globally.
iCoat Medical Operations AB
Developing drugs to improve organ transplantation outcomes globally.
GLYCOREX TRANSPLANTATION AB (PUBL)
10–19 medarbejdereDevelops technology to remove blood antibodies for transplants and disease.
Circio AB
Developing circular RNA expression systems for enhanced gene therapies.
Sangair AB
3 medarbejdereDeveloping revolutionary blood treatment technology to combat severe sepsis infections.
Udforsk mere
Spørgsmål om ITB-MED AB
Vil du se Funnelfeedr i aktion?
Book en gratis demo og opdag, hvordan Funnelfeedr hjælper dig med at finde og konvertere dine ideelle kunder.
Book en demo